

Medicare Part D – 2016

Prior Authorization Group Description

PHENTERMINE

Covered Uses:

Short term, 8 to 12 weeks, adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index, BMI, greater than or equal to 30 kg per m² or greater than or equal 27 kg per m² in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia).

Exclusion Criteria:**Required Medical Information:**

BMI is greater than or equal to 30 kg/m² OR BMI is greater than or equal to 27 kg/m² with one or more of the following severe co-morbid conditions 1. Coronary artery/heart disease 2. Diabetes 3. Dyslipidemia 4. Hypertension 5. Obstructive sleep apnea

Age Restrictions:**Prescriber Restrictions:****Coverage Duration:**

Three months.

Other Criteria:

Failure or clinically significant adverse events to Xenical.